Clinical trial · no report yet · Phase 1
NCT05029882
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
- NCT05029882 ↗
- Active, not recruiting
- AbbVie
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer; Advanced Solid Tumors; Gastroesophageal Adenocarcinoma; Colorectal Cancer
- Interventions
- ABBV-400; Trifluridine/Tipiracil; Bevacizumab
- Arms
- Part 1 (Monotherapy Dose Escalation) · Experimental
- Part 2i (wtEGFR Non-Small Cell Lung Cancer [NSCLC]) · Experimental
- Part 2ii (mutEGFR NSCLC) · Experimental
- Part 2iii (Squamous NSCLC) · Experimental
- Part 3 (Gastroesophageal Adenocarcinoma/Gastroesophagel Junct · Experimental
- Part 4 (Colorectal Cancer) · Experimental
- Part 5 (MET Amplification) · Experimental
- Part 6 (MET Mutation) · Experimental
- Part 7a (Combination Dose Escalation) · Experimental
- Part 7bi (Combination Dose Optimization Low Dose) · Experimental
- Part 7bii (Combination Dose Optimization High Dose) · Experimental
- Part 7biii (Combination Comparator) · Experimental
- Enrollment
- 520
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- AbbVie
- Start
- Oct 13, 2021
- Primary completion
- Nov 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05029882 · updated Oct 29, 2025
Publications
linked from the registry- Sharma MR, Powderly J, Kuboki Y, Strickler JH, Perets R, Cohen JE, Raimbourg J, Nakajima TE, Yamamoto N, Cruz-Correa M, O'Neil B, Ghiringhelli F, Raghav K, Cecchini M, Bar J, Hunter Z, Burns M, Blaney M, Morrison-Thiele G, Aristide MN, Freise KJ, Li R, Li M, Vasilopoulos A, Biesdorf C, Sommerhalder D. Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. J Clin Oncol. 2026 Jul 10;44(20):1876-1888. doi: 10.1200/JCO-25-01525. Epub 2026 May 1. PubMed 42066233